Bioclinica, a Princeton-based provider of clinical trial development solutions, has combined its medical and scientific affairs units into one organization overseen by Dr. Michael O’Neal, newly named chief medical officer.
The company said the medical and scientific affairs team will have individual practice leaders for each area, with a shared services organization for improvement initiatives, all under O’Neal’s oversight.
O’Neal had been head of oncology for the firm since 2006.
“Transitioning to this new operating design would not be possible without the collective capabilities of our medical and scientific affairs teams,” Chairman and CEO Euan Menzies said in a prepared statement. “This will allow us to continue to provide superior support and service for all clients, while also looking to drive improved utilization of technology across all aspects of our work.”
The company also said Dr. Julie Cole now will lead the oncology team as VP of oncology and medical imaging, while Dr. Klaus Noever will support the team in Europe.
